June 2007
Worldwide Biotech;Jun2007, Vol. 19 Issue 6, p8
Trade Publication
The article reports on the exclusive licensing agreement between ArQule Inc. and Kyowa Hakko Kogyo Co. Ltd. ArQule have entered into to develop and commercialize ARQ 197 in Japan and parts of Asia. ARQ 197 is a small molecule, selective inhibitor of the c-Met receptor tyrosine kinase. The deal includes $123 million in upfront and potential development milestone payments from Kyowa to ArQule, including a $30 million cash upfront licensing payment.


Related Articles

  • Licensing Update.  // PharmaWatch: Biotechnology;Jan2006, Vol. 5 Issue 1, p15 

    This article presents licensing updates of pharmaceutical companies. BioWa Corp., which is a subsidiary of one of Japan's largest biotech companies Kyowa Hakko Kogyo Co. Ltd., has licensed its Potelligent technology to Medlmmune Inc., a Maryland-based drugmaker, for use in its research programs....

  • Amgen Pays $520M to Kyowa for CCR4 Antibody.  // Bioworld Week;3/10/2008, Vol. 16 Issue 10, p1 

    The article reports on the $520 million payment for the licensing of KW-0761 chemokine C-C motif receptor 4 (CCR4) antibody to Kyowa Hakko Kogyo Co. Ltd. by Amgen Inc. in California. It is part of the initiatives in expanding its clinical pipeline throughout the international market except some...

  • Amgen Gaining Rights to CCR4 Antibody in $520M Kyowa Deal. Boggs, Jennifer // BioWorld Today;3/7/2008, Vol. 19 Issue 46, p1 

    The article reports on the addition of a CCR4 antibody to the clinical line of products of Amgen Inc. The company obtained a license for the antibody from Kyowa Hakko Kogyo Co. Ltd. in exchange for $100 million and up to $420 million in milestones. The deal enables Amgen to obtain worldwide...

  • ArQule Partners ARQ 197 In Asia In Potential $123M Collaboration. Shrine, Jim // BioWorld Today;4/30/2007, Vol. 18 Issue 83, p1 

    The article reports on a partnership formed by ArQule Inc. with Kyowa Hakko Kogyo Co. Ltd. Under the partnership, Kyowa Hakko will have the exclusive rights to the cancer agent ARQ197 in South Korea, China, Japan and Taiwan. The deal also gives ArQule maximum flexibility on partnering decisions....

  • ArQule Partners ARQ 197 In Potential $123M Deal.  // Bioworld Week;5/7/2007, Vol. 15 Issue 19, p2 

    The article reports on the agreement between ArQule Inc. and Kyowa Hakko Kogyo Co. Ltd. to partner on the lead program from ArQule's Cancer Survival Protein modulation program. It states that ArQule gets $30 million up front in the deal, and Kyowa gets exclusive rights to the cancer agent ARQ...

  • Kyowa Hakko expands.  // Chemical Market Reporter;12/22/97, Vol. 252 Issue 25, p3 

    Reports that Kyowa Hakko Kogyo Co. Ltd. has launched a major expansion at the Yokkaichi and Chiba, Japan facilities of its subsidiary, Kyowa Yuka Co. Ltd.

  • Kyowa Hakko expands and targets amino acids. Mirasol, Feliza // Chemical Market Reporter;09/14/98, Vol. 254 Issue 11, p5 

    Reports that Kyowa Hakko USA of New York, the marketing arm of Kyowa Hakko Kogyo CO. Ltd., is investing heavily in research and development and core technologies in the amino acids market. Factors influencing the growth of the amino acids market; Worldwide demand for amino acids in...

  • Kyowa Hakko Launches Antibodies Unit. Scott, Alex // Chemical Week;2/26/2003, Vol. 165 Issue 8, p27 

    Reports on the launching of BioWa, a subsidiary of Kyowa Hakko Kogyo which focus on monoclonal antibodies. Information on the monoclonal antibodies production of the subsidiary; Function of its antibody technology.

  • plastics & coatings In Brief.  // Chemical Market Reporter;3/11/2002, Vol. 261 Issue 10, p8 

    Presents news briefs on the plastics and coatings industry as of March 11, 2002. Decision of TDI Bayer Corp.'s polyurethanes division to raise prices for its Mondur toluene diisocyanate products; Performance of Kyowa Hakko Kogyo Co.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics